Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

Phase 2

Completed

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma
Contiguous Stage II Small Lymphocytic Lymphoma
Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma
Peripheral T-cell Lymphoma
Recurrent Adult Acute Myeloid Leukemia
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Childhood Acute Myeloid Leukemia
Recurrent Childhood Lymphoblastic Lymphoma

Interventions: Biological: alemtuzumab
Drug: fludarabine phosphate
Radiation: total-body irradiation
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Drug: mycophenolate mofetil
Drug: cyclosporine

First Posted Date: 2003-01-27

Last Posted Date: 2020-01-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 60

Registration Number: NCT00040846

Locations: 🇮🇹
University of Torino, Torino, Italy
🇺🇸
Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States
🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

and more 4 locations

Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer

Phase 2

Completed

Conditions: Cervical Cancer
Vaginal Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2010-04-02

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00005941

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Phase 1

Completed

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

First Posted Date: 2003-01-27

Last Posted Date: 2010-03-10

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Registration Number: NCT00006042

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2010-02-24

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 54

Registration Number: NCT00005580

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
New York Presbyterian Hospital - Cornell Campus, New York, New York, United States
🇺🇸
Massey Cancer Center, Richmond, Virginia, United States

Non-Ablative Allo HSCT For Hematologic Malignancies or SAA

Phase 2

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Precancerous/Nonmalignant Condition
Small Intestine Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2011-12-08

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 58

Registration Number: NCT00006379

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2003-01-27

Last Posted Date: 2011-11-30

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00006233

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2011-11-30

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00027547

Locations: 🇺🇸
Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States
🇩🇪
Universitaet Leipzig, Leipzig, Germany
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia

Phase 3

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2008-07-24

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Registration Number: NCT00017108

Locations: 🇧🇪
Hopital Universitaire Erasme, Brussels, Belgium
🇭🇺
County Hospital, Kaposvar, Hungary
🇳🇱
Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands

and more 10 locations

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer

Interventions: Biological: filgrastim
Biological: therapeutic allogeneic lymphocytes
Drug: cyclophosphamide
Drug: fludarabine phosphate
Drug: methotrexate
Drug: tacrolimus
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2016-07-14

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 36

Registration Number: NCT00027573

Locations: 🇺🇸
CCOP - Mayo Clinic Scottsdale Oncology Program, Scottsdale, Arizona, United States
🇺🇸
CCOP - Oklahoma, Tulsa, Oklahoma, United States
🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

and more 3 locations

Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma

Phase 2

Completed

Conditions: Lymphoma
Leukemia

Interventions: Drug: fludarabine phosphate
Drug: Cyclophosphamide
Biological: PBSC
Drug: G-CSF
Biological: Donor lymphocytes

First Posted Date: 2003-01-27

Last Posted Date: 2016-07-18

Lead Sponsor: Cancer and Leukemia Group B

Target Recruit Count: 47

Registration Number: NCT00006252

Locations: 🇺🇸
UMASS Memorial Cancer Center - University Campus, Worcester, Massachusetts, United States
🇺🇸
Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees, Voorhees, New Jersey, United States
🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States

and more 16 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy